Detalhe da pesquisa
1.
3K3A-Activated Protein C Variant Does Not Interfere With the Plasma Clot Lysis Activity of Tenecteplase.
Stroke
; 51(7): 2236-2239, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32568648
2.
Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke.
Ann Neurol
; 85(1): 125-136, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30450637
3.
Stroke Treatment With PAR-1 Agents to Decrease Hemorrhagic Transformation.
Front Neurol
; 12: 593582, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33790846
4.
Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic stroke.
Curr Pharm Des
; 18(27): 4215-22, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22632606